Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P48382
UPID:
RFX5_HUMAN
Alternative names:
Regulatory factor X 5
Alternative UPACC:
P48382; B7Z848; D3DV19; E9PFU4; Q5VWC3
Background:
DNA-binding protein RFX5, also known as Regulatory factor X 5, plays a pivotal role in the immune system. It activates transcription from class II MHC promoters, recognizes X-boxes, and mediates cooperative binding between RFX and NF-Y. RFX binds the X1 box of MHC-II promoters, highlighting its crucial role in the regulation of immune response.
Therapeutic significance:
RFX5 is directly linked to Bare lymphocyte syndrome 2, a severe immunodeficiency disease characterized by a profound defect in MHC II expression and an extreme susceptibility to infections. Understanding the role of DNA-binding protein RFX5 could open doors to potential therapeutic strategies for this and related immune disorders.